Skip to content

Asset turnover at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.5×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.4×0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
0.3×+0.2×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
0.3×0.0×
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
0.1×-0.2×

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Calculated from Kymera Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's asset turnover?
Kymera Therapeutics (KYMR) reported asset turnover of 0× in Q1 2026.
How has Kymera Therapeutics's asset turnover changed year-over-year?
Kymera Therapeutics's asset turnover decreased by 39.6% year-over-year, from 0.1× to 0×.
What is the long-term trend for Kymera Therapeutics's asset turnover?
Over 5 years (2020 to 2025), Kymera Therapeutics's asset turnover has grown at a -23.9% compound annual growth rate (CAGR), from 0.1× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.